Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 15 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 33 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 15 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 33 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride provides potassium ions for essential cellular functions, including maintenance of intracellular tonicity, nerve impulse conduction, cardiac and skeletal muscle contraction, and acid-base balance. Dextrose supplies glucose for cellular energy metabolism, and sodium chloride provides sodium and chloride ions to maintain extracellular fluid volume and osmolality.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult maintenance: 100-200 mL/hour, providing potassium at 1.5-3 mEq/hour, not to exceed 10 mEq/hour or 200 mEq/day.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Potassium: Not applicable (homeostatically regulated); dextrose: ~1-2 hours (exogenous insulin clearance); chloride: ~3-4 hours.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Primarily renal excretion of potassium (90% via kidneys); chloride and dextrose components are metabolized or excreted renally. Less than 1% fecal.
Category C
Category A/B
Electrolyte
Electrolyte